PQE-GROUP
PQE Group, a multinational consulting corporation operating on the side of Pharmaceutical and Medical Device Quality, and Techniconsult Group, an engineering company, are both leaders in the Life Science industry and have signed a cross-holding agreement, strengthening their presence on the national and international market. The partnership brings together two matchless companies holding the market’s high spot.
Both companies are Italian excellences from Tuscany and family-run businesses with numerous points in common. Their goal is to make their skills and expertise available to clients and the Pharmaceutical industry for successful engineering integrated projects, becoming a point of attraction for worldwide talents and companies. The Companies also pay particular attention to the values they share, with an emphasis on CSR activities and the well-being of their workforce, which counts 2000 people worldwide, of which 1000 are in Italy.
Techniconsult Group, founded in Florence in 1987, is becoming a benefit company, with a turnover of 27 million euros (+36% compared to 2021). The company has been supporting its clients for over 30 years in the design, management, and building of pharmaceutical facilities, studying and applying efficient and smart engineering solutions through a flexible approach.
Techniconsult’s model integrates perfectly with the know-how developed by PQE, a giant consulting company for the Pharma industry, with a turnover prediction for 2022 of more than 90 millions euro (+68% compared to 2021). Thanks to its international reach and reputation, it has brought the Made in Italy brand to the world. The financial maneuver that the companies have agreed on consists of shares exchanges that will deeply integrate the two companies with the goal of growing together.
This operation is part of the PQE Federation path, a concept internally developed by PQE Group founder Gilda D’Incerti, which aims to create a global network with vertical specializations in the Pharma industry that are able to offer its clients integrated and complementary solutions. The same reasoning has been adopted by Techniconsult Group owners Rosario Lo Presti and Pier Angelo Galligani, who, in the last years, have signed various agreements in Italy and other countries to secure the position of their company as a first-class vendor in the Pharmaceutical field.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005021/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philip Morris International Publishes Updated Climate Transition Plan to Achieve Net Zero by 20403.11.2025 11:00:00 CET | Press release
The plan details actions, timelines, and targets for climate change mitigation and adaptation in the company’s direct operations and the most vulnerable areas of its supply chain Philip Morris International Inc. (PMI) (NYSE: PM) today announced the release of its second Climate Transition Plan (CTP 2025), presenting an updated and integrated strategy to achieve net-zero greenhouse gas (GHG) emissions across its value chain by 2040. The new plan reflects PMI’s continued commitment to a low-carbon future while aligning with science, regulatory frameworks, and stakeholder expectations, and builds on its 2021 Low-Carbon Transition Plan. Further, building on its 2022 Task Force on Climate-related Financial Disclosures (TCFD) report, the CTP 2025 details the results of a comprehensive climate change risks and opportunities (CCRO) assessment PMI conducted in 2024. “This Climate Transition Plan reinforces our commitment to sustainability as a fundamental business driver at PMI—one that is inte
SLB Unveils Groundbreaking New Agentic AI Technology for the Energy Industry3.11.2025 11:00:00 CET | Press release
Global energy technology company SLB (NYSE: SLB) today announced the launch of Tela™, an agentic AI assistant purpose-built to transform the upstream energy sector. Tela leverages agentic AI to not only automate processes but transform workflows and drive better business outcomes. Tela will be embedded in SLB’s portfolio of applications and platforms, and users will interact through a simple conversational interface. This approach enables agentic AI to act as a proactive collaborator — augmenting the workforce to achieve greater productivity and efficiency at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103326704/en/ Tela follows a common five-step agentic AI loop: observe, plan, generate, act and learn. This allows agents within Tela to proactively interact with their environment, adapt to new data, and continuously improve outcomes. Whether interpreting well logs, predicting drilling issues, or optimizing equip
KCAS Bio Strengthens Board of Directors with Appointment of Paul Kirchgraber and Kurt Doyle3.11.2025 09:30:00 CET | Press release
KCAS Bio, a leading contract research organization (CRO) specializing in comprehensive bioanalytical and biomarker services, is delighted to announce the appointment of Dr. Paul Kirchgraber and Mr. Kurt Doyle to its Board of Directors. Their addition marks a significant milestone in KCAS Bio’s continued growth and strategic evolution in the global life sciences industry. KCAS Bio is headquartered in the Kansas City, Kansas metropolitan area with operating sites in the greater Philadelphia area; Lyon, France; and a partnership in Melbourne, Australia. The Company is backed by Vitruvian Partners, one of the world’s leading growth-focused investment firms. Dr. Paul Kirchgraber brings decades of leadership experience in clinical research and laboratory operations. He served as Executive Vice President and CEO of Covance, Labcorp’s Drug Development Division, where he led global teams in drug and medical device development in over 60 countries. Dr. Kirchgraber has experience running global p
Eric Jing: Ant Group to Strengthen Support for Hong Kong's Global Finance and Tech Leadership with AI, GoGlobal Services3.11.2025 09:19:00 CET | Press release
Eric Jing, Chairman of Ant Group, reaffirmed Ant’s commitment to deepening cross-sector collaboration on regulated AI and tokenization innovation in the territory, and to expanding its cross-border payment and trade financing services to support Hong Kong’s initiative to help Chinese businesses go global. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251102787084/en/ John Lee, Chief Executive of Hong Kong SAR visited the booths of Ant International and Ant Digital Technologies during the 10th annual Hong Kong Fintech Week on November 3, 2025. Speaking on a panel with Christopher Hui, Hong Kong’s Secretary for Financial Services and the Treasury, and Fred Hu, Founder, Chairman and CEO of Primavera Capital Group at the 10th annual Hong Kong Fintech Week on November 3, 2025, Jing said the City’s visionary and prudent approach to policy innovation, rich commercial and financial use cases and a robust ecosystem of cross-sector c
Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region3.11.2025 09:00:00 CET | Press release
Julie Dehaene-Puype joins Kyowa Kirin as new President of the International RegionJeremy Morgan will retire at the end of December 2025 after a two-month leadership transition period Kyowa Kirin International (“KKI”), a group company of Kyowa Kirin Co., Ltd. (TSE:4151, “Kyowa Kirin”), a Japan-based Global Specialty Pharmaceutical Company, today announced the appointment of Julie Dehaene-Puype as President for the Region, effective 1 November 2025. Julie follows the tenure of Jeremy Morgan, who has served as President for the International Region since 2023. Morgan will serve in an advisor role to the business through to the end of 2025, working in partnership with Dehaene-Puype to ensure a successful and smooth change for the company. “We are very pleased to welcome Julie to the company in the role as President of KKI,” said Tomohiro Sudo, Chief International Business Officer of Kyowa Kirin. “Julie joins us with extensive experience in global biotech and pharma spanning a 25-year caree
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
